ACOR Financial Facts

Net loss per share-diluted (earnings per share): 0.21
Total operating expenses: 127.03M
See Full Income Statement

Trade accounts receivable, net: -60.64M
Non-current portion of deferred license revenue: -96.61M
See Full Balance Sheet

Acorda Therapeutics, Inc. (ACOR) Earnings

  |   Expand Research on ACOR
Next EPS Date 8/1/16 *Est. EPS Growth Rate -53.3% *Last Qtr.
Average EPS % Beat Rate +50.9% Revenue Growth Rate +16.1% *Last Qtr.
Average % Move 1-Wk after EPS +2.1% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
2/11/16 Q415 $0.28$0.22 +$0.06$130.9M$128.24M N/A Details
10/22/15 Q315 $0.31$0.15 +$0.16$148.2M$115.52M N/A Details
4/28/16 Q116 $0.07$0.08 -$0.01$115.9M$115.36M N/A Details
7/30/15 Q215 $0.31$0.17 +$0.14$105.5M$110.84M N/A Details
2/12/15 Q414 $0.46$0.14 +$0.32$117.9M$110.8M N/A Details
4/30/15 Q115 $0.15$0.14 +$0.01$99.85M$100.2M N/A Details
10/30/14 Q314 $0.28$0.05 +$0.23$106M$94.7M N/A Details
7/31/14 Q214 $0.42$0.15 +$0.27$97.13M$91.4M N/A Details